Comparative efficacy of two doses of nebulized coli stimethate for the eradication of Pseudomonas aeruginosa in children with cystic fibrosis

Canadian Respiratory Journal

Volumn 14, Issue 8, 2007, Pages 473-479

  Brochet, Marie Sophie ^a   McDuff, Anne Catherine ^a   Bussières, Jean François ^a   Caron, Elaine ^a   Fortin, Geneviève ^a   Lebel, Denis ^a   Marcotte, Jacques Édouard ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Colistimethate; Cystic fibrosis; Pseudomonas aeruginosa; Pulmonary function tests

Indexed keywords

AMINOGLYCOSIDE; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIMETHATE; IMIPENEM; PENICILLIN G; PLACEBO; QUINOLONE DERIVATIVE; TOBRAMYCIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; CHILD; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DETERIORATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; INFANT; LUNG FUNCTION TEST; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SIDE EFFECT; SORE THROAT; THORAX PAIN; TREATMENT DURATION; VOICE;

EID: 39149097203     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/673976     Document Type: Article

References (50)

1. Bosso JA. Cystic fibrosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach, 4th edn. Connecticut: Appleton & Lange, 1999:508-20.
2. Döring C, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur Respir J 2000;16:749-67.
3. Hart CA, Beeching NJ, Duerden BI. Respiratory infections. J Med Microbiol 2002;51:903-14.
4. Wagener JS, Headley AA. Cystic fibrosis: Current trends in respiratory care. Respir Care 2003;48:23-7.
5. Williams CN. Cystic fibrosis: Genotype phenotype correlations and future genetic therapy. Can J Gastroenterol 1998;12:474-5.
6. Canadian Cystic Fibrosis Foundation. Report of the Canadian Patient Data Registry, 2000. Toronto: Canadian Cystic Fibrosis Foundation, 2001.
7. LiPuma JJ. Expanding microbiology of pulmonary infection in cystic fibrosis. Pediatr Infect Dis J 2000;19:471-4.
8. Burns JL, Gibson RL, McNamara S. Longitudinal assesment of Pseudomonas aeruginosa in young children with cystic fibrosis. Infect Dis 2001;183:444-52.
9. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early Pseudomonas colonization in cystic fibrosis. Lancet 1985;1:865.
10. Heijerman H. Infection and inflammation in cystic fibrosis: A short review. J Cyst Fibros 2005;4(Suppl 2):3-5.
11. Banerjee D, Stableforth. The treatment of respiratory pseudomonas infection in cystic fibrosis. Drugs 2000;60:1053-64.
12. Høiby N. Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis. Paediatr Drugs 2000;2:451-63.
13. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001;7:434-40.
14. Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005;4(Suppl 2):49-54.
15. Management of respiratory Pseudomonas infections in cystic fibrosis: Many strategies to consider. Drug Ther Perspect 2001;17:5-9.
16. Littlewood JM, Koch C, Lambert PA, et al. A ten year review of colomycin. Respir Med 2000;94:632-40.
17. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-6.
18. Fredericksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-5.
19. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8.
20. Vazquez C, Municio M, Corera M, Gaztelurrutia L, Sojo A, Vitoria JC. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatr 1993;82:308-9.
21. ME Hodson, CG Gallagher, JR Goven. Randomised UK/Eire clinical trial of the efficacy and safety of tobramycin 300 mg/5 mL nebulizer solution or nebulised colistin in CF patients. 24th European Cystic Fibrosis Conference. Stockholm, June 4 to 8, 2000.
22. Hodson ME, Gallagher CG, Govan JRW. A randomized clinical trial of nebulized tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-64.
23. Salcedo A, Giron RM, Beltran B, Martinez A, Maiz L, Suarez L; Fundacion Sira Carrasco. [Consensus conference: Home intravenous antibiotic treatment for cystic fibrosis. The Sira Carrasco Foundation. 26 April 2002.] Arch Bronconeumol 2003;39:469-75.
24. Elphick HE, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database Syst Rev 2005;(2):CD002007.
25. Sermet-Gaudelus I, Le Cocguic Y, Ferroni A, et al. Nebulized antibiotics in cystic fibrosis. Pediatr Drugs 2002;4:455-67.
26. Toso C, Williams DM, Noone PG. Inhaled antibiotics in cystic fibrosis: A review. Ann Pharmacother 1996;30:840-50.
27. Campbell PW III, Saiman L. Use of aerosolized antibiotics in patients with cystic fibrosis. Chest 1999;116:775-88.
28. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003;(3):CD001021.
29. Webb AK, Dodd ME. Nebulised antibiotics for adults with cystic fibrosis. Thorax 1997;52(Suppl 2):S69-71.
30. Moss RB. Administration of aerolized antibiotics in cystic fibrosis patients. Chest 2001;120:S107-13.
31. Coly-Mycin M Product Monograph. Kirkland: Pfizer Canada Inc, 2001.
32. Thomson Micromedex. "Colistin" DRUGDEX System. (Version current at October 18, 2007).
33. Isenberg HD, Baron EJ, D'Amato RF. Recommendations for isolations of bacteria from clinical specimens. In: Manual of Clinical Microbiology, 5th edn. Washington, DC: American Society for Microbiology, 1991:216-21.
34. Gilligan PH. Report on the consensus document for microbiology and infectious diseases in cystic fibrosis. Clin Microbiol Newsl 1996;18:83-7.
35. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991;4:35-51.
36. Aronoff SC, Beall RJ, Burns JL, et al. Microbiology and infectious disease in cystic fibrosis, Consensus Conference on Microbiology and Infectious Disease in Cystic Fibrosis. Bethesda: Cystic Fibrosis Foundation, 1994;5:2-26.
37. Sahm DF, Washington JA. Antibacterial susceptibility tests: Dilution methods. In: Manual of Clinical Microbiology, 5th edn. Washington, DC: American Society for Microbiology, 1991:1105-16.
38. Isenberg HD. Clinical Microbiology Procedures Handbook. Washington DC: American Society for Microbiology, 1994.
39. National Committee for Clinical Laboratory Standards. Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standards M7-A2. Villanova: National Committee for Clinical Laboratory Standards, 1990.
40. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997;39:255-60.
41. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. Eur Respir J 2005;26:153-61.
42. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
43. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26:511-22.
44. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon dioxide uptake in the lung. Eur Respir J 2005;26:720-35.
45. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
46. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerolized colistin. Am J Respir Crit Care Med 2000;162:328-30.
47. Döring C, Hoiby N; Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: A European consensus. J Cyst Fibros 2004;3:67-91.
48. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704.
49. Munck A, Bonacorsi S, Matiani-Kurkdjian P, et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001;32:288-92.
50. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: Randomized controlled trial. J Pediatr 2002;140:299-305.